PacBio should return to growth over time, says Canaccord
Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...